Miscellaneous Malignancies | Norton Healthcare

Indication: Miscellaneous Malignancies

A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell Carcinoma

Advanced Malignancies

Sub-indication: Triple Negative Breast Cancer, Renal Cell Carcinoma

Line of Therapy: 1st line

Drug Study

Principal Investigator: Jeffrey Hargis, M.D.
Norton Cancer Institute

Sponsor: Infinity Pharmaceuticals

Learn more at ClinicalTrials.gov

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.